Acute Medication Management for Symptomatic Bradycardia
For symptomatic bradycardia with hemodynamic compromise, administer atropine 0.5-1 mg IV as first-line therapy, repeatable every 3-5 minutes up to a maximum of 3 mg 1, 2.
First-Line Treatment: Atropine
Atropine is the primary medication for acute symptomatic bradycardia, working as a parasympatholytic agent that blocks muscarinic acetylcholine receptors to increase sinus node automaticity 2. The ACC/AHA/HRS guidelines give this a Class IIa recommendation for patients with sinus node dysfunction causing symptoms or hemodynamic compromise 1, 2.
Dosing specifics:
- Initial dose: 0.5-1 mg IV bolus
- Repeat every 3-5 minutes as needed
- Maximum total dose: 3 mg
- Half-life: approximately 2 hours 2
Recent evidence from 2025 confirms that moderate doses (0.5-1.0 mg) appear safe with no reports of paradoxical worsening of bradycardia 3. The current practice of using 0.5 mg as an initial dose is clinically reasonable and well-supported 3.
Critical contraindication: Do not use atropine in heart transplant patients without evidence of autonomic reinnervation—this carries a Class III: Harm recommendation as it can cause paradoxical effects 1, 2.
Second-Line Agents: Catecholamines
When atropine fails or in patients at low risk for coronary ischemia, consider beta-agonists (Class IIb recommendation) 1, 2:
Dopamine
- Dosing: Start at 5 mcg/kg/min IV, increase by 5 mcg/kg/min every 2 minutes
- Range: 5-20 mcg/kg/min for chronotropic effect
- Caution: Doses >20 mcg/kg/min risk vasoconstriction and arrhythmias 1, 2
Isoproterenol
- Dosing: 20-60 mcg IV bolus, then 10-20 mcg doses, or continuous infusion 1-20 mcg/min
- Advantage: Pure beta-agonist without vasopressor effect
- Monitor: Closely for ischemic chest pain development 1, 2
Epinephrine
- Dosing: 2-10 mcg/min IV or 0.1-0.5 mcg/kg/min, titrated to effect
- Note: Strong alpha-adrenergic effects 1, 2
Cause-Specific Treatments
The guidelines emphasize treating reversible causes first (Class I recommendation) 1:
Calcium Channel Blocker Overdose
- 10% calcium chloride: 1-2 g IV every 10-20 minutes or infusion 0.2-0.4 mL/kg/h
- 10% calcium gluconate: 3-6 g IV every 10-20 minutes or infusion 0.6-1.2 mL/kg/h 1, 2
Beta-Blocker or Calcium Channel Blocker Overdose
- Glucagon: 3-10 mg IV bolus with infusion of 3-5 mg/h
- High-dose insulin: 1 unit/kg IV bolus, then 0.5 units/kg/h infusion (monitor glucose and potassium closely) 1, 2
Digoxin Toxicity
- Digoxin antibody fragments: Dose based on amount ingested or serum concentration (one vial binds ~0.5 mg digoxin) 1, 2
Post-Heart Transplant or Spinal Cord Injury
- Aminophylline: 6 mg/kg in 100-200 mL IV over 20-30 minutes, or 250 mg IV bolus for AV block with inferior MI
- Theophylline: 300 mg IV, then oral 5-10 mg/kg/day titrated to effect 1, 2
Clinical Algorithm
- Assess reversibility: Identify and treat medication toxicity, electrolyte abnormalities, or other reversible causes first
- If symptomatic/hemodynamically unstable: Give atropine 0.5-1 mg IV immediately (unless post-transplant)
- If inadequate response: Repeat atropine every 3-5 minutes (max 3 mg total)
- If still inadequate: Start dopamine 5 mcg/kg/min or isoproterenol infusion
- If refractory: Consider temporary transcutaneous/transvenous pacing while arranging permanent pacemaker evaluation
Important Caveats
Avoid catecholamines in patients at high risk for coronary ischemia, as these agents can precipitate myocardial ischemia 1, 2. The guidelines specifically note this concern with isoproterenol.
Temporary transvenous pacing carries significantly higher adverse event rates (19.1% vs 3.4%) compared to early permanent pacemaker placement, including central line infections and cardiac arrest 4. If pacing is needed, move quickly toward permanent pacemaker rather than prolonged temporary pacing.
Weekend admissions are associated with delays in permanent pacemaker placement and increased use of temporary pacing—advocate for early definitive management rather than bridging strategies 4.
For chronic management, theophylline (400-600 mg/day in divided doses) can be considered in elderly patients who refuse or cannot tolerate pacemaker placement 5, though this is not addressed in acute guidelines.